CDI Global
Person name

Gary Epler

CDI Global Partner

Experience & Qualifications

Experience & Qualifications


Gary R. Epler, M.D., is a partner at CDI Global North America, with extensive experience in M&A with a focus on healthcare including MedTech, medical devices, biotech and genomics diagnostics, and specialty pharma.


Dr. Gary Epler is an internationally known Harvard Medical School professor and bestselling author who has impacted the lives of people throughout the world through his speaking engagements, six health books, teaching, and consulting. He has been called upon by individuals from around the globe who have a rare lung disease called BOOP that he discovered. He has developed the "Eplerian Philosophy" which is a modern-day way of life for people to live their best lives at home, at work, and in society defined as “know who you are moment by moment.” He has worked at the Centers for Disease Control (CDC) in Atlanta; discovered a lung fluke parasite in Colombia, South America; and was Chairman, Department of Medicine. He has been recognized yearly since 1994 in The Best Doctors in America and one of Boston Magazine’s “Top Doctors in Town.” He is a radio and television personality, and a Hollywood screenwriter for a medical thriller movie. Dr. Epler is a successful serial entrepreneur as a founder and CEO of three companies including a biotech company, a nutraceutical company, and a health management company. Dr. Epler is an award-winning speaker, addressing audiences about health, productivity, and leadership.


Dr. Gary Epler can be reached at or at + 1 617 680 0650.

Connect with a CDI Expert. Request a Call Back.

News & Insights

Read more

June 5, 2023

CDI Global You Tube Channel Launched

Read more

May 25, 2023

CDI Americas Meeting

Part 3 of Interview with David Wanetick: The importance of valuing intellectual property in pricing M&A transactions
What makes software companies so relevant for investors and what sub-sectors are most attractive
CDI announces new African Partner: Africa Merchant Capital Advisory Limited